Influenza A/H1N1 Vaccine in Patients Treated by Kidney Transplant or Dialysis

• DOI: 10.2215/cjn.04670511
• Publication Date: 2011-09-16T10:32:59Z
• Authors: Nilufer E. Broeders; Anneleen Hombrouck; Anne Lemy; Karl Martin Wissing; Judith Racapé; Karine Gastaldello; Annick Massart; Steven Van Gucht; Laura Weichselbaum; Aurelie De Mul; Bernard Brochier; Isabelle Thomas; Daniel Abramowicz
• Keywords: Seroconversion

Summary Background and objectives In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There are few data concerning immunogenicity or security of adjuvanted-A/H1N1 vaccine in transplanted hemodialyzed patients. Design, setting, participants, & measurements Sera from 21 controls, 53 (HD) patients, 111 renal transplant recipients (RT) were sampled before (T0) 1 month after (T1) a single dose Pandemrix® (GSK Biologicals, AS03-adjuvanted). We measured neutralizing antibodies against A/H1N1/2009, geometric mean (GM) titers, GM titer ratios (T1/T0) with 95% confidence intervals, seroconversion rate (responders: ≥4-fold increase titer). The HLA MICA immunization was determined by Luminex technology. Results ratio 38 (19 to 78), 9 (5 16), 5 (3 6) HD RT respectively ( P < 0.001). proportion responders 90%, 57%, 44%, prevalence histocompatibility leukocyte antigen (HLA) class I, II, MHC I-related chain A immunization, was, respectively, 15%, 14%, 14% 11% vaccination = 1, 0.39). Conclusions A/H1N1-adjuvanted is limited efficacy but safe disease populations. humoral response lower versus Further studies needed improve those